Company / R&D per Share
Glaukos Corp. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$2.67
FY2025
5-year range
$1.51 / $2.78
FY2021-FY2025
Trend
-3.9%
vs FY2024
Sector context
#31 of 108
Health Care
What the data says
At $2.67, Glaukos Corp.'s r&d per share ranks #31 of 108 in the Health Care sector. Improved from $2.11 to $2.67 over the past 2 years.
Based on SEC 10-K filings.
2.67 in FY2025 with a 5-year CAGR of +18.5%.
Improved from $2.11 to $2.67 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +13.6%
- 5-Year CAGR
- +18.5%
- 10-Year CAGR
- -
Sector benchmark
#31 of 108 in Health CareTop 29% of 108This company $2.67 Sector average $2.07
▼
+28.7% above sector average
Key checks
Key Insights
- In FY2025, r&d per share decreased 3.9% year-over-year.
- Ranks #31 out of 108 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2024.
- Lowest r&d per share in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.67 | -3.9% |
| FY2024 | $2.78 | +31.3% |
| FY2023 | $2.11 | +16.3% |
| FY2022 | $1.82 | +20.4% |
| FY2021 | $1.51 | +32.2% |
| FY2020 | $1.14 | +6.0% |
| FY2019 | $1.08 | +27.6% |
| FY2018 | $0.84 | +14.4% |
| FY2017 | $0.74 | -18.7% |
| FY2016 | $0.91 | -85.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026